1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K., and Washington State -nCo V.C.I.T., First Case of 2019 Novel Coronavirus in the United States. N Engl J Med, 2020. 382(10): p. 929-936 PMID: 32004427; PMC7092802 DOI: 10.1056/NEJMoa2001191.
2. Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., Legrand M., and Deutschman C.S., Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med, 2020. 8(12): p. 1233-1244 PMID: 33075298; PMC7567529 DOI: 10.1016/S2213-2600(20)30404-5.
3. Moore J.B. and June C.H., Cytokine Release Syndrome in Severe COVID 19: Lessons From Arthritis and Cell Therapy in Cancer Patients Point to Therapy for Severe Disease. 2020, WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MD BETHESDA United States.
4. Cavalli G., De Luca G., Campochiaro C., Della-Torre E., Ripa M., Canetti D., Oltolini C., Castiglioni B., Tassan Din C., Boffini N., Tomelleri A., Farina N., Ruggeri A., Rovere-Querini P., Di Lucca G., Martinenghi S., Scotti R., Tresoldi M., Ciceri F., Landoni G., Zangrillo A., Scarpellini P., and Dagna L., Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol, 2020. 2(6): p. e325-e331 PMID: 32501454; PMC7252085 DOI: 10.1016/S2665-9913(20)30127-2.
5. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., and Hlh Across Speciality Collaboration U.K., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395(10229): p. 1033-1034 PMID: 32192578; PMC7270045 DOI: 10.1016/S0140-6736(20)30628-0.
6. Fu B., Xu X., and Wei H., Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med, 2020. 18(1): p. 164 PMID: 32290839; PMC7154566 DOI: 10.1186/s12967-020-02339-3.
7. Frey N., Cytokine release syndrome: Who is at risk and how to treat. Best Pract Res Clin Haematol, 2017. 30(4): p. 336-340 PMID: 29156206; DOI: 10.1016/j.beha.2017.09.002.
8. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., Xavier R., Zemel L., Baildam E., Burgos-Vargas R., Dolezalova P., Garay S.M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A., Printo, and Prcsg, Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med, 2012. 367(25): p. 2385-95 PMID: 23252525; DOI: 10.1056/NEJMoa1112802.
9. Sheppard M., Laskou F., Stapleton P.P., Hadavi S., and Dasgupta B., Tocilizumab (Actemra). Hum Vaccin Immunother, 2017. 13(9): p. 1972-1988 PMID: 28841363; PMC5612212 DOI: 10.1080/21645515.2017.1316909.
10. Xu X., Han M., Li T., Sun W., Wang D., and Fu B., Effective treatment of severe COVID-19 patients with Tocilizumab.[ChinaXiv: 202003.00026]. 2020, DOI.
11. Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., Franceschini E., Cuomo G., Orlando G., Borghi V., Santoro A., Di Gaetano M., Puzzolante C., Carli F., Bedini A., Corradi L., Fantini R., Castaniere I., Tabbi L., Girardis M., Tedeschi S., Giannella M., Bartoletti M., Pascale R., Dolci G., Brugioni L., Pietrangelo A., Cossarizza A., Pea F., Clini E., Salvarani C., Massari M., Viale P.L., and Mussini C., Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol, 2020. 2(8): p. e474-e484 PMID: 32835257; PMC7314456 DOI: 10.1016/S2665-9913(20)30173-9.
12. Gupta S., Wang W., Hayek S.S., Chan L., Mathews K.S., Melamed M.L., Brenner S.K., Leonberg-Yoo A., Schenck E.J., Radbel J., Reiser J., Bansal A., Srivastava A., Zhou Y., Finkel D., Green A., Mallappallil M., Faugno A.J., Zhang J., Velez J.C.Q., Shaefi S., Parikh C.R., Charytan D.M., Athavale A.M., Friedman A.N., Redfern R.E., Short S.A.P., Correa S., Pokharel K.K., Admon A.J., Donnelly J.P., Gershengorn H.B., Douin D.J., Semler M.W., Hernan M.A., Leaf D.E., and Investigators S.-C., Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med, 2021. 181(1): p. 41-51 PMID: 33080002; PMC7577201 DOI: 10.1001/jamainternmed.2020.6252.
13. Nassar M., Nso N., Alfishawy M., Novikov A., Yaghi S., Medina L., Toz B., Lakhdar S., Idrees Z., Kim Y., Gurung D.O., Siddiqui R.S., Zheng D., Agladze M., Sumbly V., Sandhu J., Castillo F.C., Chowdhury N., Kondaveeti R., Bhuiyan S., Perez L.G., Ranat R., Gonzalez C., Bhangoo H., Williams J., Osman A.E., Kong J., Ariyaratnam J., Mohamed M., Omran I., Lopez M., Nyabera A., Landry I., Iqbal S., Gondal A.Z., Hassan S., Daoud A., Baraka B., Trandafirescu T., and Rizzo V., Current systematic reviews and meta-analyses of COVID-19. World Journal of Virology, 2021. 10(4): p. 182-208 PMID: DOI: 10.5501/wjv.v10.i4.182.
14. Koike R., Harigai M., Atsumi T., Amano K., Kawai S., Saito K., Saito T., Yamamura M., Matsubara T., and Miyasaka N., Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Modern rheumatology, 2009. 19(4): p. 351-357 PMID.
15. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., Kumar J., Tesoriero J., Weinberg P., Kirkwood J., Muse A., DeHovitz J., Blog D.S., Hutton B., Holtgrave D.R., and Zucker H.A., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA, 2020. 323(24): p. 2493-2502 PMID: 32392282; PMC7215635 DOI: 10.1001/jama.2020.8630.
16. Paranjpe I., Fuster V., Lala A., Russak A.J., Glicksberg B.S., Levin M.A., Charney A.W., Narula J., Fayad Z.A., and Bagiella E., Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. Journal of the American College of Cardiology, 2020. 76(1): p. 122-124 PMID.
17. Singh A.K., Majumdar S., Singh R., and Misra A., Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes Metab Syndr, 2020. 14(5): p. 971-978 PMID: 32610262; PMC7320713 DOI: 10.1016/j.dsx.2020.06.054.
18. Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castelli F., Franceschini F., Airo P., Bazzani C., Beindorf E.A., Berlendis M., Bezzi M., Bossini N., Castellano M., Cattaneo S., Cavazzana I., Contessi G.B., Crippa M., Delbarba A., De Peri E., Faletti A., Filippini M., Filippini M., Frassi M., Gaggiotti M., Gorla R., Lanspa M., Lorenzotti S., Marino R., Maroldi R., Metra M., Matteelli A., Modina D., Moioli G., Montani G., Muiesan M.L., Odolini S., Peli E., Pesenti S., Pezzoli M.C., Pirola I., Pozzi A., Proto A., Rasulo F.A., Renisi G., Ricci C., Rizzoni D., Romanelli G., Rossi M., Salvetti M., Scolari F., Signorini L., Taglietti M., Tomasoni G., Tomasoni L.R., Turla F., Valsecchi A., Zani D., Zuccala F., Zunica F., Foca E., Andreoli L., and Latronico N., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev, 2020. 19(7): p. 102568 PMID: 32376398; PMC7252115 DOI: 10.1016/j.autrev.2020.102568.
19. Ragab D., Salah Eldin H., Taeimah M., Khattab R., and Salem R., The COVID-19 cytokine storm; what we know so far. Frontiers in immunology, 2020. 11: p. 1446 PMID.
20. Capra R., De Rossi N., Mattioli F., Romanelli G., Scarpazza C., Sormani M.P., and Cossi S., Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med, 2020. 76: p. 31-35 PMID: 32405160; PMC7219361 DOI: 10.1016/j.ejim.2020.05.009.
21. Bhimraj A., Morgan R.L., Shumaker A.H., Lavergne V., Baden L., Cheng V.C., Edwards K.M., Gandhi R., Muller W.J., O'Horo J.C., Shoham S., Murad M.H., Mustafa R.A., Sultan S., and Falck-Ytter Y., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis, 2020 PMID: 32338708; PMC7197612 DOI: 10.1093/cid/ciaa478.
22. Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., and Pazdur R., FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist, 2018. 23(8): p. 943-947 PMID: 29622697; PMC6156173 DOI: 10.1634/theoncologist.2018-0028.
23. Libby P. and Simon D.I., Inflammation and thrombosis: the clot thickens. 2001, Am Heart Assoc.
24. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S., and China Medical Treatment Expert Group for C., Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020. 382(18): p. 1708-1720 PMID: 32109013; PMC7092819 DOI: 10.1056/NEJMoa2002032.
25. Jackson D.J., Busse W.W., Bacharier L.B., Kattan M., O'Connor G.T., Wood R.A., Visness C.M., Durham S.R., Larson D., Esnault S., Ober C., Gergen P.J., Becker P., Togias A., Gern J.E., and Altman M.C., Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol, 2020. 146(1): p. 203-206 e3 PMID: 32333915; PMC7175851 DOI: 10.1016/j.jaci.2020.04.009.
26. Liu S., Zhi Y., and Ying S., COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol, 2020. 59(1): p. 78-88 PMID: 32468411; DOI: 10.1007/s12016-020-08797-3.
27. Wang G., Wu C., Zhang Q., Wu F., Yu B., Lv J., Li Y., Li T., Zhang S., and Wu C. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. in Open Forum Infectious Diseases. 2020. Oxford University Press US.
28. Klopfenstein T., Zayet S., Lohse A., Balblanc J.-C., Badie J., Royer P.-Y., Toko L., Mezher C., Bossert M., and Bozgan A.-M., Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine et Maladies Infectieuses, 2020 PMID.
29. Biran N., Ip A., Ahn J., Go R.C., Wang S., Mathura S., Sinclaire B.A., Bednarz U., Marafelias M., and Hansen E., Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology, 2020 PMID.
30. Kewan T., Covut F., Al-Jaghbeer M.J., Rose L., Gopalakrishna K.V., and Akbik B., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine, 2020. 24: p. 100418 PMID: 32766537; PMC7305505 DOI: 10.1016/j.eclinm.2020.100418.
31. Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D., Criner G.J., Kaplan-Lewis E., Baden R., Pandit L., Cameron M.L., Garcia-Diaz J., Chavez V., Mekebeb-Reuter M., Lima de Menezes F., Shah R., Gonzalez-Lara M.F., Assman B., Freedman J., and Mohan S.V., Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med, 2021. 384(1): p. 20-30 PMID: 33332779; PMC7781101 DOI: 10.1056/NEJMoa2030340.
32. Review P., Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. 2020 PMID.
33. Stone J.H., Frigault M.J., Serling-Boyd N.J., Fernandes A.D., Harvey L., Foulkes A.S., Horick N.K., Healy B.C., Shah R., Bensaci A.M., Woolley A.E., Nikiforow S., Lin N., Sagar M., Schrager H., Huckins D.S., Axelrod M., Pincus M.D., Fleisher J., Sacks C.A., Dougan M., North C.M., Halvorsen Y.D., Thurber T.K., Dagher Z., Scherer A., Wallwork R.S., Kim A.Y., Schoenfeld S., Sen P., Neilan T.G., Perugino C.A., Unizony S.H., Collier D.S., Matza M.A., Yinh J.M., Bowman K.A., Meyerowitz E., Zafar A., Drobni Z.D., Bolster M.B., Kohler M., D'Silva K.M., Dau J., Lockwood M.M., Cubbison C., Weber B.N., Mansour M.K., and Investigators B.B.T.T., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med, 2020. 383(24): p. 2333-2344 PMID: 33085857; PMC7646626 DOI: 10.1056/NEJMoa2028836.
34. Veiga V.C., Prats J.A., Farias D.L., Rosa R.G., Dourado L.K., Zampieri F.G., Machado F.R., Lopes R.D., Berwanger O., and Azevedo L.C., Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. bmj, 2021. 372 PMID.
35. Horby P.W., Pessoa-Amorim G., Peto L., Brightling C.E., Sarkar R., Thomas K., Jeebun V., Ashish A., Tully R., and Chadwick D., Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Medrxiv, 2021 PMID.
36. Kaye A.G. and Siegel R., The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. PeerJ, 2020. 8: p. e10322 PMID: 33194450; PMC7643559 DOI: 10.7717/peerj.10322.
37. Michot J.M., Albiges L., Chaput N., Saada V., Pommeret F., Griscelli F., Balleyguier C., Besse B., Marabelle A., Netzer F., Merad M., Robert C., Barlesi F., Gachot B., and Stoclin A., Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol, 2020. 31(7): p. 961-964 PMID: 32247642; PMC7136869 Abbvie, Agios, Amgen, Astex, AstraZeneca, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Forma, Genentech, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Oncopeptides AB, Roche, Sanofi, Taiho, and Xencor, outside the submitted work, and personal fees or travel grants or ad-board: Astex, Iqone, Mundipharma, and Bristol-Myers Squibb, outside the submitted work. BB reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals, outside the submitted work. CR reports personal fees for advisory boards from Bristol-Myers Squibb (BMS), Pierre Fabre, Novartis, Amgen, Merck, and Roche, outside the submitted work. FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. AM reports sponsored research at Gustave Roussy Cancer Center with: Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor, outside the submitted work. DOI: 10.1016/j.annonc.2020.03.300.
38. Zhang C., Wu Z., Li J.W., Zhao H., and Wang G.Q., Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents, 2020. 55(5): p. 105954 PMID: 32234467; PMC7118634 DOI: 10.1016/j.ijantimicag.2020.105954.
39. Pinzon R.T., Wijaya V.O., and Buana R.B., Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Infect Public Health, 2021. 14(8): p. 1001-1009 PMID: 34153723; PMC8204364 DOI: 10.1016/j.jiph.2021.06.004.
40. Castelnovo L., Tamburello A., Lurati A., Zaccara E., Marrazza M.G., Olivetti M., Mumoli N., Mastroiacovo D., Colombo D., Ricchiuti E., Vigano P., Paola F., and Mazzone A., Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience. Medicine (Baltimore), 2021. 100(1): p. e23582 PMID: 33429732; PMC7793456 DOI: 10.1097/md.0000000000023582.
41. De Rossi N., Scarpazza C., Filippini C., Cordioli C., Rasia S., Mancinelli C.R., Rizzoni D., Romanelli G., Cossi S., Vettoretto N., Bove S., Manfredini S., Beindorf E.A., Mosca C., Scipione V., Flamminio G., Albini E.A., Giansiracusa P., and Capra R., Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine, 2020. 25: p. 100459 PMID: 32838235; PMC7366117 DOI: 10.1016/j.eclinm.2020.100459.
42. Atallah B., El Nekidy W., Mallah S.I., Cherfan A., AbdelWareth L., Mallat J., and Hamed F., Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers. Thromb J, 2020. 18: p. 22 PMID: 32922212; PMC7479301 DOI: 10.1186/s12959-020-00236-9.
43. Di Nisio M., Potere N., Candeloro M., Spacone A., Pieramati L., Ferrandu G., Rizzo G., La Vella M., Di Carlo S., Cibelli D., Parruti G., Levi M., and Porreca E., Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. Eur J Intern Med, 2021. 83: p. 34-38 PMID: 33162299; PMC7608031 DOI: 10.1016/j.ejim.2020.10.020.
44. Papamichalis P., Papadogoulas A., Katsiafylloudis P., Skoura A.L., Papamichalis M., Neou E., Papadopoulos D., Karagiannis S., Zafeiridis T., Babalis D., and Komnos A., Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report. Int J Infect Dis, 2020. 97: p. 90-93 PMID: 32497796; PMC7263262 DOI: 10.1016/j.ijid.2020.05.118.
45. Tomasiewicz K., Piekarska A., Stempkowska-Rejek J., Serafińska S., Gawkowska A., Parczewski M., Niścigorska-Olsen J., Łapiński T.W., Zarębska-Michaluk D., Kowalska J.D., Horban A., and Flisiak R., Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Ther, 2021. 19(1): p. 93-100 PMID: 32693650; PMC7441800 DOI: 10.1080/14787210.2020.1800453.
46. Price C.C., Altice F.L., Shyr Y., Koff A., Pischel L., Goshua G., Azar M.M., McManus D., Chen S.C., Gleeson S.E., Britto C.J., Azmy V., Kaman K., Gaston D.C., Davis M., Burrello T., Harris Z., Villanueva M.S., Aoun-Barakat L., Kang I., Seropian S., Chupp G., Bucala R., Kaminski N., Lee A.I., LoRusso P.M., Topal J.E., Dela Cruz C., and Malinis M., Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest, 2020. 158(4): p. 1397-1408 PMID: 32553536; PMC7831876 DOI: 10.1016/j.chest.2020.06.006.
47. Luo P., Liu Y., Qiu L., Liu X., Liu D., and Li J., Tocilizumab treatment in COVID-19: A single center experience. J Med Virol, 2020. 92(7): p. 814-818 PMID: 32253759; PMC7262125 DOI: 10.1002/jmv.25801.